ME
IART icon

McIlrath & Eck’s Integra LifeSciences IART Stock Holding History

McIlrath & Eck’s Portfolio IART Stock Details IART Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		– Sell
-70
Closed -$2.04K – 994
2024
Q2 		$2.04K Hold
70
– – ﹤0.01% 823
2024
Q1 		$2.48K Buy
+70
New +$2.8K ﹤0.01% 803

Other funds holding IART

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Fuller & Thaler Asset Management
Fuller & Thaler Asset Management San Mateo, California $29.7B AUM 43.33% 1-Year Est. Return
AllianceBernstein
AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
SHCM
Sachem Head Capital Management New York $4.15B AUM 48.05% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

McIlrath & Eck's IART Position: Q3 2024 in Review

McIlrath & Eck sold out of Integra LifeSciences (IART) in Q3 2024, closing a stake of 70 shares — an estimated $2.04K sold.

McIlrath & Eck first reported a position in IART in Q1 2024 and held it in 2 quarters. The position peaked at $2.48K in Q1 2024. 225 funds tracked by Wall St. Rank hold IART as of Q3 2024.

  • McIlrath & Eck reported no remaining Integra LifeSciences position as of Q3 2024 after selling out during the quarter.
  • McIlrath & Eck sold 70 Integra LifeSciences shares in Q3 2024, an estimated $2.04K.
  • McIlrath & Eck first reported a position in Integra LifeSciences in Q1 2024 and held it in 2 quarters.
  • McIlrath & Eck's Integra LifeSciences position peaked at $2.48K in Q1 2024.
  • 225 funds tracked by Wall St. Rank held Integra LifeSciences as of Q3 2024.

Based on McIlrath & Eck's 13F filing for Q3 2024, filed 19 Nov 2024.